Royalty Pharma plc
NASDAQ:RPRX
32.77 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 594 | 564.69 | 537.267 | 567.978 | 596 | 536.313 | 538.202 | 683.971 | 565.748 | 573.463 | 535.955 | 562.049 | 575.7 | 585.773 | 554.963 | 573.027 | 571 | 539 | 510.932 | 500.879 | 457.486 | 464.277 | 457.608 | 434.883 |
| Cost of Revenue
| 0 | 1.654 | 6 | 583.6 | 76.513 | 277.137 | 241.228 | 118.804 | 5.67 | 305.061 | 105.714 | 5.67 | 266.505 | 5.796 | 5.733 | 5.671 | 129.341 | 5.796 | 5.733 | 88.012 | 919.16 | 122.338 | 72.21 | 50.033 |
| Gross Profit
| 594 | 563.036 | 531.267 | -15.622 | 519.487 | 259.176 | 296.974 | 565.167 | 560.078 | 268.402 | 430.241 | 556.379 | 309.195 | 579.977 | 549.23 | 567.356 | 441.659 | 533.204 | 505.199 | 412.867 | -461.674 | 341.939 | 385.398 | 384.85 |
| Gross Profit Ratio
| 1 | 0.997 | 0.989 | -0.028 | 0.872 | 0.483 | 0.552 | 0.826 | 0.99 | 0.468 | 0.803 | 0.99 | 0.537 | 0.99 | 0.99 | 0.99 | 0.773 | 0.989 | 0.989 | 0.824 | -1.009 | 0.736 | 0.842 | 0.885 |
| Reseach & Development Expenses
| 1 | 0.5 | 0.5 | 0.5 | 1 | 50.5 | 0.5 | 0.5 | 50.5 | 25.5 | 0.606 | 100.5 | 103.821 | 90.5 | 3.122 | 2.641 | 8 | 5 | 5.776 | 7.639 | 15.87 | 22.718 | 21.457 | 22.991 |
| General & Administrative Expenses
| 68 | 56.72 | 54.708 | 57.652 | 59.185 | 57.234 | 47.634 | 85.695 | 73.228 | 50.692 | 51.843 | 51.54 | 46.161 | 48.588 | 44.921 | 43.156 | 50 | 51 | 42.799 | 38.065 | 23.061 | 25.603 | 30.349 | 24.426 |
| Selling & Marketing Expenses
| 0 | 0 | 0.292 | 0 | -0.185 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 68 | 56.72 | 54.708 | 57.652 | 59 | 57.234 | 47.634 | 85.695 | 73.228 | 50.692 | 51.843 | 51.54 | 46.161 | 48.588 | 44.921 | 43.156 | 50 | 51 | 42.799 | 38.065 | 23.061 | 25.603 | 30.349 | 24.426 |
| Other Expenses
| 163 | -227.604 | -212.429 | -583.6 | 77 | -1.707 | 1.091 | 118.804 | 308.848 | 305.061 | 105.714 | 190.291 | -4.82 | -0.793 | -0.107 | 0.043 | 80 | 131 | 0.261 | -5.923 | 0.14 | 0.232 | -0.037 | 0.058 |
| Operating Expenses
| 232 | -170.384 | 267.637 | 641.752 | -17 | 384.871 | 289.362 | 204.999 | 432.576 | 381.253 | 158.163 | 342.331 | 422.283 | 282.721 | -189.986 | 343.73 | 258 | 28 | 101.586 | 139.449 | -874.433 | -68.221 | 129.749 | 3.983 |
| Operating Income
| 362 | 735.074 | 269.63 | -73.774 | 613 | 151.442 | 248.84 | 478.972 | 95.339 | 192.21 | 227.642 | 219.718 | 153.417 | 303.052 | 744.949 | 229.297 | 314 | 511 | 409.346 | 361.43 | 1,331.919 | 532.498 | 327.859 | 430.9 |
| Operating Income Ratio
| 0.609 | 1.302 | 0.502 | -0.13 | 1.029 | 0.282 | 0.462 | 0.7 | 0.169 | 0.335 | 0.425 | 0.391 | 0.266 | 0.517 | 1.342 | 0.4 | 0.55 | 0.948 | 0.801 | 0.722 | 2.911 | 1.147 | 0.716 | 0.991 |
| Total Other Income Expenses Net
| -28 | 71.284 | -75.253 | 69.501 | 104.69 | -29.365 | 102.496 | 30.117 | -127.375 | 28.204 | 113.805 | -91.635 | -99.746 | -81.256 | 61.806 | -70.318 | 52.573 | 113.687 | 192.63 | -252.334 | 114.609 | -92.471 | -149.089 | -34.806 |
| Income Before Tax
| 334 | 806.358 | 194.377 | -4.273 | 718 | 122.077 | 351.336 | 509.089 | -610.03 | 220.414 | 491.597 | 128.083 | 53.671 | 221.796 | 806.755 | 158.979 | 367 | 624 | 601.976 | 109.096 | 1,446.528 | 440.027 | 178.77 | 396.094 |
| Income Before Tax Ratio
| 0.562 | 1.428 | 0.362 | -0.008 | 1.205 | 0.228 | 0.653 | 0.744 | -1.078 | 0.384 | 0.917 | 0.228 | 0.093 | 0.379 | 1.454 | 0.277 | 0.643 | 1.158 | 1.178 | 0.218 | 3.162 | 0.948 | 0.391 | 0.911 |
| Income Tax Expense
| 126 | 0 | 92.373 | -9.051 | 223 | 49.963 | 123.711 | 168.334 | 0.139 | 2.582 | 187.093 | 167.957 | 46.974 | 119.867 | 365.979 | 89.86 | -531.38 | 333.622 | 159.902 | 76.443 | 78.813 | 92.031 | 88.044 | 90.445 |
| Net Income
| 208 | 543.987 | 102.004 | 4.778 | 494.34 | 72.114 | 227.625 | 340.755 | -610.169 | 217.832 | 304.504 | -39.874 | 7.904 | 101.929 | 440.776 | 69.119 | 171 | 291 | 442.074 | 71.24 | 1,420.396 | 408.982 | 151.713 | 367.444 |
| Net Income Ratio
| 0.35 | 0.963 | 0.19 | 0.008 | 0.829 | 0.134 | 0.423 | 0.498 | -1.079 | 0.38 | 0.568 | -0.071 | 0.014 | 0.174 | 0.794 | 0.121 | 0.299 | 0.54 | 0.865 | 0.142 | 3.105 | 0.881 | 0.332 | 0.845 |
| EPS
| 0.46 | 1.61 | 0.23 | 0.011 | 1.11 | 0.16 | 0.51 | 0.76 | -1.38 | 0.36 | 0.5 | -0.066 | 0.016 | 0.24 | 1.08 | 0.18 | 0.44 | 0.79 | 1.25 | 0.2 | 4.01 | 1.15 | 0.43 | 1.04 |
| EPS Diluted
| 0.35 | 1.21 | 0.23 | 0.011 | 1.11 | 0.16 | 0.5 | 0.76 | -1.38 | 0.36 | 0.5 | -0.066 | 0.011 | 0.24 | 1.08 | 0.11 | 0.44 | 0.79 | 1.25 | 0.2 | 4.01 | 1.15 | 0.43 | 1.04 |
| EBITDA
| 362 | 872.864 | 560 | 39.959 | 673.865 | 168.11 | 398.285 | 556.039 | -606.04 | 267.391 | 538.563 | 225.388 | 83.445 | 308.848 | 750.682 | 234.968 | 393.004 | 516.363 | 415.08 | 367.163 | 1,337.715 | 538.294 | 333.592 | 437.499 |
| EBITDA Ratio
| 0.609 | 1.546 | 0.502 | -0.13 | 1.029 | 0.313 | 0.511 | 0.771 | 0.299 | 0.335 | 0.725 | 0.416 | 0.221 | 0.552 | 1.41 | 0.436 | 0.72 | 1.226 | 0.876 | 0.709 | 2.908 | 1.152 | 0.721 | 1.016 |